By LabPulse.com staff writers

June 10, 2019 -- The Association for Molecular Pathology (AMP) has broadened the criteria it wants to see for clinically meaningful genomic tests for consumers in an updated position statement published on June 10.

The organization outlined what it needs to support direct testing for medical purposes, as an update to its last position statement on the topic in 2015. The criteria include the following:

  • Health claims must be clinically validated.
  • Testing providers must comply with CLIA regulations.
  • Tests must be interpreted by board-certified molecular laboratory professionals.

The AMP is also calling for the inclusion of information about analytical and clinical validity of testing in marketing materials and adherence to best practices on privacy.

The AMP said it continues to be neutral on recreational and ancestry testing for the public and to "strongly oppose consumer genomic testing that provides information that is either not clinically valid or is used to sell secondary products or services, such as unsubstantiated claims concerning athleticism, diet, exercise, or cosmetics."

AMP, CAP show labs what they need to include in CYP2C9 tests
Labs should be including a broad set of CYP2C9 alleles in their own genotype tests, according to new joint recommendations published May 7 by the...
Aussie wellness firm myDNA makes U.S. debut
Australian personal wellness business myDNA is rolling out its genetic testing kits for consumers in the U.S., including personal reports on how to use...
Arivale pulls plug on test-based personal wellness business
Seattle-based start-up Arivale has closed its personal wellness business, which offered blood and genetic assays directly to consumers. The firm said...

Copyright © 2019 LabPulse.com

Last Updated np 6/10/2019 12:58:18 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email